Adult Considerations in Spinal Muscular Atrophy: Building Clinician and Patient Medical TeamsPremiere Date: Wednesday, November 9, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, November 9, 2023
|Claudia A. Chiriboga, MD, MPH, FAAN (Moderator)
Professor of Neurology and Pediatrics
Division of Pediatric Neurology
Columbia University Medical Center
New York, NY
|Vanessa Battista, DNP, MBA, MS, RN, CPNP-PC
Senior Nursing Director, Palliative Care
Dana Farber Cancer Institute
Department of Psychosocial Oncology & Palliative Care
Pediatric Nurse Practitioner
|Tina Duong, PT, PhD
Director, Clinical Outcomes Research & Development
Division of Neuromuscular Medicine
Adults now make up more than a quarter of patients with spinal muscular atrophy (SMA), a debilitating genetic disease characterized by progressive muscle weakness and atrophy, but advances in research, supportive care, and disease-modifying therapies have largely centered on pediatric populations. Consequently, adults with SMA often face “fragmented” care pathways that are particularly problematic when transitioning from pediatric to adult care.
In this educational webcast, expert faculty will discuss treatment needs of adult patients with SMA and the unique challenges and experiences of those patients transitioning from pediatric to adult care. The webcast will also include insights about how to navigate systems and utilize the most up-to-date and appropriate therapeutic approaches for adult patients with SMA.
At the end of this CE activity, participants should be able to:
- Evaluate the burden of SMA on adult patients including clinical, quality of life (QoL), and psychological/psychosocial outcomes.
- Develop best practice interdisciplinary strategies to meet the needs of patients with SMA transitioning from pediatric to adult care.
- Integrate appropriate therapeutic approaches to care for adult patients with SMA.
Supported by an educational grant from Genentech, a member of the Roche Group.
Neurologists, neuromuscular specialists, PAs, NPs, physical therapists, and adult patients with SMA.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Dr. Chiriboga reports the following financial relationships:
Advisory Board/Consultant: Genentech, Inc.; Novartis Pharmaceuticals Corporation; PTC Therapeutics; and Roche
Research Support: AveXis, Inc./Novartis Gene Therapies; Biogen; and Roche
Speakers Bureau: Biogen Colombia; Genentech, Inc.; and Roche
Dr. Battista reports the following financial relationships:
Advisory Board: Biogen and Novartis Pharmaceuticals Corporation
Speakers Bureau: Novartis Pharmaceuticals Corporation
Dr. Duong reports the following financial relationships:
Advisory Board: ActiGraph, LLC; Astellas Pharma Inc.; Avidity Biosciences; Biogen; Dyne Therapeutics; Genentech, Inc.; Pfizer Inc.; Roche; Sanofi; Sarepta Therapeutics, Inc.; and Scholar Rock, Inc.
Consultant: Astellas Pharma Inc.; ATOM; Genentech, Inc.; Roche; and TRiNDS
Grants: Biogen and Ionis Pharmaceuticals, Inc.
Research Support: Biogen
Speakers Bureau: Genentech, Inc. and Sarepta Therapeutics, Inc.
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).